Overview

A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)

Status:
Recruiting

Trial end date:
2027-09-30

Target enrollment:

Participant gender:

Summary

The study is being conducted to compare JS004 plus Toripalimab with Investigator-Selected Chemotherapy in Patients with PD-(L)1 monoclonal antibody refractory Classic Hodgkin Lymphoma (cHL)

Phase:

Phase 3

Details

Lead Sponsor:

Shanghai Junshi Bioscience Co., Ltd.

Treatments:

Bendamustine Hydrochloride
Gemcitabine